P2D Bioscience has received a $320,000 grant from the U.S. National Heart, Lung and Blood Institute. The purpose of this grant is to develop a novel class of anti-inflammatory drugs specifically targeting lung diseases, including acute lung injury/acute respiratory distress syndrome, chronic obstructive pulmonary disease (COPD) and asthma. Click here to read the entire release. […]
P2D Bioscience has received a $1.5 million grant from the National Institutes of Health (NIH) to develop its lead dopamine transport inhibitor, PD2007, through IND safety and toxicology studies for future use in humans. More than a decade of preclinical testing and numerous scientific publications indicate PD2007’s efficacy at inhibiting dopamine transport in multiple brain […]
P2D Bioscience’s lead compounds, PD2005 and PD2007, have received U.S. and Canadian patent protection for treating Attention Deficit/Hyperactivity Disorder (ADHD). The patents contain ADHD-use claims for the entire family of P2D’s first-in-class dopamine transport inhibitors, including PD2005 and PD2007. Click here to read entire release Tweet
P2D Bioscience (P2D, Inc.), a pharmaceutical development company, today announced that its lead Attention Deficit/Hyperactivity Disorder (ADHD) stimulant drug, PD2005, demonstrated efficacy in treating the core symptoms of ADHD in preclinical ADHD models. The independently conducted studies were funded by a grant from the National Institutes of Health (NIH). Click here to read the entire […]
